Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endocrine therapies for symptomatic benign prostatic hyperplasia

J E Oesterling1

  • 1Department of Urology, Mayo Clinic, Rochester, Minnesota.

Urology
|February 1, 1994
PubMed
Summary

Endocrine therapies like 5 alpha-reductase inhibitors show promise for benign prostatic hyperplasia (BPH) by reducing prostate size with minimal side effects. Other treatments targeting androgenic or estrogenic stimulation are also under investigation for BPH management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

The Journal of urology·1999
Same author

Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

The Journal of urology·1999
Same author

Have complication rates decreased after treatment for localized prostate cancer?

The Journal of urology·1999
Same author

Reference ranges for serum prostate-specific antigen in black and white men without cancer.

Urology·1998
Same author

Understanding artificial neural networks and exploring their potential applications for the practicing urologist.

Urology·1998
Same author

Screening digital rectal examination and prostate cancer mortality: a population-based case-control study.

Urology·1998

Area of Science:

  • Urology
  • Endocrinology
  • Pharmacology

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition in aging men.
  • Hormonal factors, including androgens and estrogens, play a significant role in BPH development and progression.
  • Current BPH treatments aim to alleviate symptoms and improve quality of life.

Purpose of the Study:

  • To review and synthesize information on emerging endocrine therapies for symptomatic BPH.
  • To evaluate the efficacy, safety, and scientific rationale of various hormonal treatments.
  • To identify promising therapeutic strategies for BPH management.

Main Methods:

  • Systematic review of peer-reviewed medical and urologic literature.
  • Analysis of data on luteinizing hormone-releasing hormone (LHRH) agonists, antiandrogens, 5 alpha-reductase inhibitors, and aromatase inhibitors.

Related Experiment Videos

  • Focus on clinical results and scientific rationale for each therapy in BPH.

    • Main Results:

    • Androgen-depriving therapies (LHRH agonists, antiandrogens, 5 alpha-reductase inhibitors) reduce prostate size by approximately 25% and offer modest symptom and flow rate improvements.
    • These therapies significantly decrease prostate-specific antigen (PSA) levels.
    • 5 alpha-reductase inhibitors exhibit the most favorable side effect profile, while LHRH agonists have the most pronounced side effects (e.g., sexual dysfunction).
    • Aromatase inhibitors target estrogenic stimulation, but clinical data for BPH treatment are currently limited.

    Conclusions:

    • Medications inducing androgen deprivation effectively reduce the static component of BPH.
    • 5 alpha-reductase inhibitors represent a promising option due to their low toxicity.
    • The therapeutic role of aromatase inhibitors in BPH requires further investigation through large-scale clinical trials.